TY - JOUR T1 - Identification of HLA Class I-binding Peptides Derived from Unique Cancer-associated Proteins by Mass Spectrometric Analysis JF - Anticancer Research JO - Anticancer Res SP - 1853 LP - 1859 VL - 33 IS - 5 AU - YUKO KAMATA AU - AKIKO KUHARA AU - TAKEO IWAMOTO AU - KAZUMI HAYASHI AU - SHIGEO KOIDO AU - TAKAHIRO KIMURA AU - SHIN EGAWA AU - SADAMU HOMMA Y1 - 2013/05/01 UR - http://ar.iiarjournals.org/content/33/5/1853.abstract N2 - Background/Aim: Since antigenic peptides of the cancer-associated antigens presented on human leukocyte antigen (HLA) molecules are recognized by specific cytotoxic T-lymphocytes, they have the potential to becoming effective peptide vaccines for cancer immunotherapy. Materials and Methods: Peptides binding to HLA-A*0201 and HLA-A*2402 obtained from human prostate cancer cells by acid-elution were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and source proteins of the peptides were determined based on the HLA-binding capacity listed on the Syfpeithi. Results: We identified TKLSA possibly derived from absent in melanoma 1-like protein (AIM1L), and RLRYT from trans-membrane protein-191C (TMEM 191C) or c20orf201. Messenger RNAs encoding these proteins were expressed in various cancer cell types but none or very few in non-cancerous tissues except for testis, cerebellum and ovary. Conclusion: HLA class I-binding peptides of unique cancer-associated proteins were identified by MS analysis, and might become a promising tool for the generation of novel cancer vaccines. ER -